Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 2/20 | 0.52 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | CHUK | O15111 | 1/20 | 0.43 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | PRKACA | P17612 | 1/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 1/20 | 0.43 |
| ▸ | PRKX | P51817 | 1/20 | 0.43 |
| ▸ | PRKG2 | Q13237 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20124856 | 1.00 | CHRNB2 (0.53) | CHRNB2CHRNA4HRH1PRKCZROCK1 | |
| Hydrochloric Acid SCHEMBL22031560 | 0.98 | CHRNB2 (0.51) | CHRNB2CHRNA4HRH1PRKCZROCK1 | |
| Hydrochloric Acid SCHEMBL20165250 | 0.98 | CHRNB2 (0.51) | CHRNB2CHRNA4HRH1PRKCZROCK1 | |
| Hydrochloric Acid SCHEMBL20165251 | 0.98 | CHRNB2 (0.51) | CHRNB2CHRNA4HRH1PRKCZROCK1 | |
| SCHEMBL18689816 | 0.89 | CHRNB2 (0.55) | CHRNB2CHRNA4HRH1PRKCZROCK1 | |
| SCHEMBL3574466 | 0.89 | HRH1 (0.66) | CHRNB2CHRNA4HRH1ROCK1ROCK2 | |
| Hydrochloric Acid SCHEMBL15476748 | 0.87 | HRH1 (0.63) | CHRNB2CHRNA4HRH1ROCK1ROCK2 | |
| SCHEMBL14862725 | 0.84 | SLC6A2 (0.53) | HRH1HTR1ASLC6A2 | |
| SCHEMBL7000861 | 0.83 | PRKCZ (0.56) | CHRNB2CHRNA4HRH1PRKCZROCK1 | |
| SCHEMBL3133920 | 0.83 | PRKCZ (0.56) | CHRNB2CHRNA4HRH1PRKCZROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4005568-B1 | SGLTS/DPP4 INHIBITOR AND APPLICATION THEREOF | DONGBAO PURPLE STAR HANGZHOU BIOPHARMACEUTICAL CO LTD (CN) | 2024-07-10 | — | — | EP | disclosed |
| US-20220204488-A1 | Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof | SANOFI (FR) | 2022-06-30 | — | — | US | disclosed |
| US-11149031-B2 | Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2021-10-19 | — | — | US | disclosed |
| US-20200361918-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR) | 2020-11-19 | — | — | US | disclosed |
| WO-2018091153-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361918-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | ESR1, CYP19A1, ESR2 | CHRNB2 2851/4885CHRNA4 3145/4885HRH1 1389/4885 |
| US-11149031-B2 | Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | ESR1, CYP19A1, ESR2 | CHRNB2 2744/4885CHRNA4 3002/4885HRH1 1180/4885 |
| US-20220204488-A1 | Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof | ESR1, CYP19A1, GPER1 | CHRNB2 2473/4885CHRNA4 2706/4885HRH1 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.